Stocks and Investing Stocks and Investing
Tue, August 23, 2022
Mon, August 22, 2022
Fri, August 19, 2022
Thu, August 18, 2022

Bradley Canino Maintained (BPMC) at Strong Buy with Increased Target to $100 on, Aug 18th, 2022


Published on 2024-10-27 22:44:50 - WOPRAI, Bradley Canino
  Print publication without navigation


Bradley Canino of Stifel, Maintained "Blueprint Medicines Corporation" (BPMC) at Strong Buy with Increased Target from $93 to $100 on, Aug 18th, 2022.

Bradley has made no other calls on BPMC in the last 4 months.



There are 9 other peers that have a rating on BPMC. Out of the 9 peers that are also analyzing BPMC, 2 agree with Bradley's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Michael Ulz of "Morgan Stanley" Maintained at Hold with Decreased Target to $65 on, Tuesday, June 14th, 2022
  • Christopher Raymond of "Piper Sandler" Maintained at Hold with Decreased Target to $65 on, Thursday, May 19th, 2022


These are the ratings of the 7 analyists that currently disagree with Bradley


  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $80 on, Wednesday, August 17th, 2022
  • Derek Archila of "Wells Fargo" Maintained at Sell with Increased Target to $41 on, Wednesday, August 17th, 2022
  • Dane Leone of "Raymond James" Maintained at Strong Buy with Decreased Target to $115 on, Wednesday, August 3rd, 2022
  • Terence Flynn of "Goldman Sachs" Maintained at Strong Buy with Increased Target to $143 on, Wednesday, August 3rd, 2022
  • Matthew Biegler of "Oppenheimer" Initiated at Buy and Held Target at $80 on, Friday, July 8th, 2022
  • David Lebowitz of "Citigroup" Downgraded from Hold to Strong Sell and Decreased Target to $41 on, Friday, June 10th, 2022
  • Eun Yang of "Jefferies" Upgraded from Hold to Strong Buy and Decreased Target to $78 on, Wednesday, June 1st, 2022